×
About 7,148 results

ALLMedicine™ Splenomegaly Center

Research & Reviews  2,266 results

Preoperative Splenic Artery Embolization for Massive Splenomegaly in Children: A Single...
https://doi.org/10.1089/lap.2022.0243
Journal of Laparoendoscopic & Advanced Surgical Technique... Rollins Z, Rehman R et. al.

Nov 30th, 2022 - Introduction: Massive splenomegaly in children can complicate minimally invasive splenectomy. Splenic artery embolization (SAE) before splenectomy has been shown to decrease splenic volume, reduce intraoperative blood loss, and decrease conversion...

C9orf72 regulates the unfolded protein response and stress granule formation by interac...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691347
Theranostics Zheng W, Wang K et. al.

Nov 29th, 2022 - Rationale: A C9orf72 hexanucleotide repeat expansion (GGGGCC) is the most common genetic origin of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Haploinsufficiency of C9orf72 has been proposed as a possible disease mechani...

Similarities and differences between Gaucher disease and acid sphingomyelinase deficien...
https://doi.org/10.1016/j.ejim.2022.11.028
European Journal of Internal Medicine; Cappellini MD, Motta I et. al.

Nov 29th, 2022 - Lysosomal storage disorders are a group of inborn errors of metabolism due to defects in proteins crucial for lysosomal function. Gaucher disease is the most common autosomal recessive lysosomal storage disorder due to mutations in the GBA1 gene, ...

Features of BSCL2 related congenital generalized lipodystrophy in China: long-term foll...
https://doi.org/10.1515/jpem-2022-0372
Journal of Pediatric Endocrinology & Metabolism : JPEM; Su X, Lin Y et. al.

Nov 27th, 2022 - Congenital generalized lipodystrophy (CGL) is a group of rare autosomal inherited diseases characterized by a widespread loss of adipose tissue. The main purpose of this study was to evaluate the features of Chinese patients with CGL2. Three patie...

HSP90 inhibitors induce cell differentiation via the ubiquitin-dependent AURKA degradat...
https://doi.org/10.1002/hon.3110
Hematological Oncology; Wang F, Zhang H et. al.

Nov 25th, 2022 - Primary myelofibrosis (PMF) is characterized by immature megakaryocytic hyperplasia, splenomegaly, extramedullary hematopoiesis and bone marrow fibrosis. Our preclinical study had demonstrated that aurora kinase A (AURKA) inhibitor MLN8237 reduced...

see more →

Guidelines  1 results

Revised diagnostic criteria and classification for the autoimmune lymphoproliferative s...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953894
Blood Oliveira JB, Bleesing JJ et. al.

Jun 12th, 2010 - Lymphadenopathy in children for which no infectious or malignant cause can be ascertained constitutes a challenging diagnostic dilemma. Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  102 results

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomono...
https://clinicaltrials.gov/ct2/show/NCT05365035

Oct 13th, 2022 - Primary Objectives: To determine the efficacy, safety and tolerability of the combination of cladribine, cytarabine and venetoclax in higher-risk MDS with excess blasts and higher-risk CMML. MDS relapsed cohort (Cohort A, N=20): MDS with Int-2 or ...

VICIS - Vienna Cirrhosis Study
https://clinicaltrials.gov/ct2/show/NCT03267615

Oct 12th, 2022 - Patients with advanced chronic liver disease (ACLD) as evident by HVPG>5mmHg or liver biopsy showing F3/F4 fibrosis or as suggested by liver stiffness measurement (LSM) ≥10kPa can be included in the VICIS study. In fact most patients will be recru...

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
https://clinicaltrials.gov/ct2/show/NCT04322383

Oct 10th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia comprising 2% of all leukemias, or approximately 1900 new cases per year in the US. BRAF V600E mutation is very common in classic HCL. HCL variant (HCLv) is wild type for BRAF an...

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-e...
https://clinicaltrials.gov/ct2/show/NCT03952039

Oct 5th, 2022 - This Phase 3, multicenter, randomized, two-arm, open-label study will include subjects with intermediate or high-risk (as per the DIPSS score) primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (post-PV MF), or post-essential thrombo...

Natural History of Noncirrhotic Portal Hypertension
https://clinicaltrials.gov/ct2/show/NCT02417740

Sep 28th, 2022 - Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induc...

see more →

News  466 results

Treatments for MCL Continue to Progress
https://www.onclive.com/view/treatments-for-mcl-continue-to-progress

Nov 18th, 2022 - As research and treatment options for patients with mantle cell lymphoma (MCL) continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step...

Dr. Goy on the Clinical Implications of Treating Indolent MCL
https://www.onclive.com/view/dr-goy-on-the-clinical-implications-of-treating-indolent-mcl

Nov 15th, 2022 - Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Services, chairman, chief physician officer, chief, Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, discusses the cl...

Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS
https://www.onclive.com/view/novel-combinations-could-spark-shift-in-treatment-paradigm-for-higher-risk-mds

Sep 27th, 2022 - Several clinical trials are exploring combination therapies that include agents such as venetoclax (Venclexta), magrolimab, sabatolimab (MBG453), and others, with the goal of improving upon the efficacy achieved with hypomethylating agents in pati...

Fast Five Quiz: Chronic Myelogenous Leukemia Management
https://www.medscape.com/viewarticle/979891

Sep 21st, 2022 - Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by a three-phase clinical course comprising an initial chronic phase, an accelerated phase, and a blast phase. Most cases of CML are diagnosed in the chronic phase, ...

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC
https://www.onclive.com/view/immunotherapy-drives-first-line-systemic-treatment-for-advanced-hcc

Sep 19th, 2022 - Evidence-based decisions have leveraged the use of immunotherapy (IO) combination atezolizumab (Tecentriq) plus bevacizumab (Avastin) for patients who receive a diagnosis of hepatocellular carcinoma (HCC). Approved in 2020, the combination has bec...

see more →

Patient Education  12 results see all →